CRP and rheumatoid arthritis: The mono therapeutic response of tocilizumab and adalimumab (anti-TNF) was comparatively evaluated in methotrexate-intolerant RA patients in a double-blind adalimumab actemra (ADACTA) study (phase 4), where the results depicted elevated LDL, CRP, DAS28 (28-joint DAS) and ESR in 6 months in greater number of patients in the tocilizumab treatment group, as compared to the adalimumab treatment group [206].